The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine
Authors:
- Chung-Hang LeungCLChung-Hang Leung
- Scott BussomSBScott Bussom
- Yung-Chi ChengYCYung-Chi Cheng
- 1 September 2007
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 72 (3) , 536-544
Abstract
β-l-Dioxolane-cytidine (l-OddC, Troxacitabine, BCH-4556), a novel l-configuration deoxycytidine analog, is under clinical trials for treating cancer. The cytotoxicity of l-OddC is dependent on the amount of the triphosphate form (l-OddCTP) in nuclear DNA. Phosphoglycerate kinase (PGK), a downstream protein of hypoxia-inducible-factor-1α (HIF-1α), is responsible for the phosphorylation of the diphosphate to the triphosphate of l-OddC. In this study, we studied the impact of hypoxia on the metabolism and the cytotoxicity of l-OddC and β-d-2′,2′-difluorodeoxycytidine (dFdC) in several human tumor cell lines including HepG2, Hep3B, A673, Panc-1, and RKO. Hypoxic treatment induced the protein expression of PGK 3-fold but had no effect on the protein expression of APE-1, dCK, CMPK, and nM23 H1. Hypoxic treatment increased l-OddCTP formation and incorporation of l-OddC into DNA, but it decreased the uptake and incorporation of dFdC, which correlated with the reduction of hENT1, hENT2, and hCNT2 expression. Using a clonogenic assay, hypoxic treatment of cells made them 2- to 3-fold more susceptible to l-OddC but not to dFdC after exposure to drugs for one generation. Dimethyloxallyl glycine enhanced the cytotoxicity of l-OddC but not dFdC in Panc-1 cells under normoxic conditions. Overexpression or down-regulation of PGK using transient transfection of pcDNA5-PGK or inducible shRNA in RKO cells affected the cytotoxicity of l-OddC but not that of dFdC. The knockdown of HIF-1α in inducible shRNA in RKO cells reduced the cytotoxicity of l-OddC but not dFdC under hypoxic conditions. In conclusion, hypoxia is an important factor that may potentiate the activity of l-OddC.Keywords
This publication has 29 references indexed in Scilit:
- Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with GemcitabineCancer Research, 2006
- The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemiaBritish Journal of Cancer, 2005
- HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxiaJournal of Experimental Medicine, 2005
- Equilibrative Nucleoside Transporter 1 Expression Is Downregulated by Hypoxia in Human Umbilical Vein EndotheliumCirculation Research, 2005
- Species Differences in Troxacitabine Pharmacokinetics and PharmacodynamicsClinical Cancer Research, 2004
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004
- Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2004
- Protein profiles associated with survival in lung adenocarcinomaProceedings of the National Academy of Sciences, 2003
- Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory LeukemiaJournal of Clinical Oncology, 2002
- A Novel Action of Human Apurinic/Apyrimidinic EndonucleaseJournal of Biological Chemistry, 2000